LIVE QUOTE |
Quotes delayed 15+ min. |
- Obama says Boosting US Jobs is Top Priority
- More Consumers Giving 'Black Friday' the Cold Shoulder
- Prepare For Large Decline In Stocks, Next Year?
- Hewlett-Packard Earnings Rise, Match Guidance
- HP Comes in As Expected; Is It Time to Buy?
- Cramer: What Monday’s Housing Number Really Means
- Why the Dollar Will Likely Stay Weak for Some Time
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- Govt issues record 2.1M recall for dropside cribs
- China planning agency OKs Shanghai Disney project
- China Eastern Airlines teams up with Alibaba
- Kinder Morgan expects to pay $4.40 annual dividend
- Mich. spammer gets 4 years in stock fraud scheme
- Icahn outbids Penn to open Fontainebleau auction
- Max Capital names new president of reinsurance ops
- Valspar fiscal 4th-quarter profit climbs
- Analog Devices 4Q earnings fall; 1Q outlook upbeat
Text Size 
WASHINGTON - The Justice Department on Monday accused Wyeth, one of the nation’s biggest drugmakers, of cheating Medicaid programs out of hundreds of millions of dollars by overcharging for a stomach acid drug.
The Justice Department and more than a dozen states have joined in two whistleblower lawsuits against the Madison, N.J.-based drug company filed in federal court in Massachusetts.
The court papers claim that between 2000 and 2006, Wyeth offered steep discounts to thousands of hospitals for two versions of Protonix, a drug that suppresses stomach acid.
By law, manufacturers of brand-name drugs are required to offer the same rebates to state Medicaid programs that they provide to other customers.
The government claims the maneuver helped the company avoid paying hundreds of millions of dollars in rebates to Medicaid, a health care program for the poor that is funded by state and federal money.
“By offering massive discounts to hospitals, but then hiding that information from the Medicaid program, we believe Wyeth caused Medicaid programs throughout the country to pay much more for these drugs than they should have,” Assistant Attorney General Tony West said in a statement.
In court papers, the government accused the drug company of bundling the intravenous version of Protonix with the oral version in sales packages to hospitals, in the hopes of making more money in the lucrative outpatient market.
Wyeth defended its pricing plan.
“The company believes that it’s pricing calculations were correct and intends to defend itself vigorously in these actions,” said Doug Petkus, a Wyeth spokesman.
The states joining the lawsuit are California, Delaware, Florida, Illinois, Indiana, Louisiana, Massachusetts, New York, Michigan, Nevada, New Hampshire, Tennessee, Texas, Virginia and Wisconsin, as well as the District of Columbia.
New York-based drugmaker Pfizer Inc. is in the process of acquiring Wyeth for more than $60 billion in a deal expected to close later this year.
Print
Email
- The show attracts a big TV audience every year, but this year it may take on even more importance.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- CNBC’s Phil LeBeau took a test drive of GM’s flagship electric car. Here’s what he thought of the Volt.
- The energy company Power Efficiency is building tools that regulate the power electric motors use.
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes